Bide Pharmatech (SH:688073) Xin Lang Cai Jing·2025-09-23 03:38Company Overview - Bid Pharma is located in Yangpu District, Shanghai, and was established on April 27, 2007. The company went public on October 11, 2022. Its main business focuses on the front end of new drug research and development, providing innovative drug molecular building blocks and scientific reagents [1]. Business Composition - The revenue composition of Bid Pharma includes: - 43.26% from molecular building block heterocyclic compounds - 23.32% from molecular building block aromatic compounds - 16.36% from molecular building block aliphatic compounds - 10.57% from catalysts and ligands - 6.49% from life science reagents [1]. Market Performance - On September 23, Bid Pharma's stock fell by 5.08%, closing at 70.03 CNY per share, with a trading volume of 36.31 million CNY and a turnover rate of 1.17%. The total market capitalization is 6.365 billion CNY [1]. Fund Holdings - Morgan Stanley's fund holds a significant position in Bid Pharma, with the "Morgan Stanley Youyue Anhe Mixed A" fund (009893) owning 68,300 shares, representing 5.92% of the fund's net value, making it the second-largest holding. The estimated floating loss today is approximately 256,300 CNY [2]. Fund Performance - The "Morgan Stanley Youyue Anhe Mixed A" fund was established on September 24, 2020, with a current size of 28.9066 million CNY. Year-to-date, it has returned 22.41%, ranking 4046 out of 8172 in its category. Over the past year, it has returned 41.52%, ranking 4017 out of 7995. Since inception, it has incurred a loss of 27.95% [2]. Fund Management - The fund manager of "Morgan Stanley Youyue Anhe Mixed A" is Zhao Weijie, who has been in the position for 4 years and 205 days. The total asset size of the fund is 305 million CNY, with the best return during his tenure being 28.14% and the worst being -30% [3].